XML 1077 R108.htm IDEA: XBRL DOCUMENT
v2.4.0.6

COMMITMENTS AND CONTINGENCIES (Details) (Daiichi Sankyo, USD $) In Millions, unless otherwise specified | 1 Months Ended | 9 Months Ended | 12 Months Ended | 1 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 30, 2011 | Sep. 30, 2012 | Dec. 31, 2011 | Jul. 31, 2011 Minimum country | Sep. 30, 2012 Minimum | Dec. 31, 2011 Minimum | Sep. 30, 2012 Maximum | Dec. 31, 2011 Maximum
Licensing Agreements |  |  |  |  |  |  |  |
Up-front fee and certain past reimbursements | $ 1.6 |  |  |  |  |  |  |
Future milestone payments payable |  | $ 10.0 | $ 10.0 |  |  |  |  |
Period for which royalties will be paid following the first commercial sale of licensed products in the country |  | 10 years | 10 years |  |  |  |  |
Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons |  | 6 months | 6 months |  |  |  |  |
Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default |  | 12 months | 12 months |  |  |  |  |
Number of countries for which regulatory approval is required by September 2011 to sell sapacitabine as per termination right waived after amendment to the agreement |  |  |  | 1 |  |  |  |
Percentage of increase in royalty due on future net sales of sapacitabine after amendment |  |  |  |  | 1.25% | 1.25% | 1.50% | 1.50%

X
- Definition Represents the milestone payments paid by the entity under certain contractual agreements. + References No definition available. + Details
Name: | cycc_LicenseAgreementMilestonePaymentsPaid
Namespace Prefix: | cycc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the notice period for the termination of license after a launch of a sapacitabine-based product, or by either party for material default. + References No definition available. + Details
Name: | cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of countries for which regulatory approval is required by September 2011 to sell sapacitabine as per termination right that counter party possessed under the provision of agreement which is waived after amendment to the agreement. + References No definition available. + Details
Name: | cycc_LicenseAgreementNumberOfCountriesForWhichRegulatoryApprovalRequiredBySeptember2011ToSellSapacitabineUnderTerminationRightWaivedAfterAmendment
Namespace Prefix: | cycc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period for which royalties will be paid following the first commercial sale of licensed products in the country. + References No definition available. + Details
Name: | cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The potential future milestone payments required to be made under certain contractual agreements. + References No definition available. + Details
Name: | cycc_LicenseAgreementPotentialFutureMilestonePayments
Namespace Prefix: | cycc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the notice period for the termination of license by the reporting entity for technical, scientific, efficacy, safety, or commercial reasons. + References No definition available. + Details
Name: | cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the increase in royalty due from the entity to the counter party on future net sales depending on the level of net sales realized. + References No definition available. + Details
Name: | cycc_LossContingenciesContingentIncreaseInRoyaltyDueOnFutureNetSales
Namespace Prefix: | cycc_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration